Lumos Diagnostics Holdings Limited (LDXHF) Discusses Commercialisation Update and Market Strategy for FebriDx in the U.S. Transcript

George Kopsiaftis

Good morning, everyone, and welcome to the Lumos Diagnostics U.S. Commercialization Investor Briefing. My name is George Kopsiaftis, and I’ll be your moderator this morning. Joining us from Lumos Diagnostics today, we have Doug Ward, Managing Director and CEO; got Paul Kase, Chief Commercial Officer; and Tommy Hall, the Director of U.S. Sales. And joining us from PHASE Scientific is Bob Gergen, Vice President of Commercial Operations. I believe you’re all in the U.S. today, so I wish you all a good evening.

Douglas Ward
CEO, MD & Director

Thank you, George. Appreciate it.

Paul Kase
Senior Vice President of Commercial Operations

Thanks, George.

George Kopsiaftis

So today, the team has quite a bit to cover, and willing to keep the presentation to around 30 to 40 minutes, allowing for questions with a target of finishing around 11:30 a.m. [Operator Instructions]

As a sidenote, given we are expecting a lot of questions today, I will be prioritizing those questions relating to today’s topic. And today’s presentation will be lodged or has been lodged with the ASX this morning, and a recording of the briefing will be made available on the Lumos website once ready.

And with that, I’d like to hand it over to Doug to get us underway.

Douglas Ward
CEO, MD & Director

All right. Thank you very much, George. Great to have Bob, Tommy and Paul on this call with me today to give you this commercial update. Next slide, please, Paul.

Next slide, again, Paul. Okay. So we